. Author manuscript; available in PMC: 2019 May 1.

Published in final edited form as: J Rheumatol. 2018 Mar 1;45(5):671–677. doi: 10.3899/jrheum.161554

Table 3.

Renal remission following conventional therapy in LN at 24 months of treatment

Renal remission criteria	Type of response	n (%)
Ordinal mALMS	CR	104 (59.1)
	PR	53 (30.1)
	No	19 (10.8)

Ordinal mBLISS-LN	CR	72 (40.9)
	PR	29 (16.5)
	No	75 (42.6)

Binary mALMS^†	Response	109 (61.9)
	No response	64 (36.4)

Binary mBLISS-LN	Response	101 (57.4)
	No response	75 (42.6)

^†

3 patients lacked sufficient data to be classified by binary mALMS criteria

CR, complete remission; mALMS, modified Aspreva Lupus Management Study; mBLISS-LN, modified Belimumab International Lupus Nephritis Study; PR, partial remission